Skip to content

Study · Non-randomized trial · 2018

5 results

Regulatory T cells are expanded by Teriparatide treatment in humans and mediate intermittent PTH-induced bone anabolism in mice.

Yu M, D'Amelio P, Tyagi AM, Vaccaro C, Li JY, Hsu E, Buondonno I, Sassi F, Adams J, Weitzmann MN, DiPaolo R, Pacifici R

EMBO reports20 Nov 2017Cited by 55 (Europe PMC)

PMID29158349 (opens in a new tab)PMCIDPMC5757282 (opens in a new tab)DOI10.15252/embr.201744421 (opens in a new tab)PepBankPUB-29158349
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

2 results from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialMechanism

    In humans, teriparatide increased regulatory T cell numbers; the abstract reports a ~two-threefold increase for humans and mice together.

    In plain wordsIn humans, teriparatide increased regulatory T cell numbers; about two to threefold was reported for humans and mice together.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseHuman regulatory T cell number
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    Regulatory T cell number increase
    2 to 3-fold
    humans and mice combined; Teriparatide and iPTH

    Source sentences

    Summary
    Here, we show that Teriparatide and iPTH cause a ~two-threefold increase in the number of regulatory T cells (Tregs) in humans and mice.
    1 context sentence
    Summary · context
    Teriparatide is a bone anabolic treatment for osteoporosis, modeled in animals by intermittent PTH (iPTH) administration, but the cellular and molecular mechanisms of action of iPTH are largely unknown.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In mice, intermittent PTH increased regulatory T cell numbers.

    In plain wordsIn mice, intermittent PTH increased regulatory T cell numbers.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseMouse regulatory T cell number
    Study

    mousen: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here, we show that Teriparatide and iPTH cause a ~two-threefold increase in the number of regulatory T cells (Tregs) in humans and mice.
    1 context sentence
    Summary · context
    Teriparatide is a bone anabolic treatment for osteoporosis, modeled in animals by intermittent PTH (iPTH) administration, but the cellular and molecular mechanisms of action of iPTH are largely unknown.

Studies that did not test the peptide alone3

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 03AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Mechanism

    In mice, blocking the regulatory T cell increase prevented the increase in bone formation induced by intermittent PTH.

    In plain wordsIn mice, blocking the regulatory T cell increase prevented the bone formation increase induced by intermittent PTH.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseTreg dependence of bone formation
    Study

    mousen: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Attesting in vivo relevance, blockade of the Treg increase in mice prevents the increase in bone formation and trabecular bone volume and structure induced by iPTH
    1 context sentence
    Summary · context
    Teriparatide is a bone anabolic treatment for osteoporosis, modeled in animals by intermittent PTH (iPTH) administration, but the cellular and molecular mechanisms of action of iPTH are largely unknown.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 04AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Mechanism

    In mice, blocking the regulatory T cell increase prevented the increase in trabecular bone volume induced by intermittent PTH.

    In plain wordsIn mice, blocking the regulatory T cell increase prevented the trabecular bone volume increase induced by intermittent PTH.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseTreg dependence of trabecular bone volume
    Study

    mousen: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Attesting in vivo relevance, blockade of the Treg increase in mice prevents the increase in bone formation and trabecular bone volume and structure induced by iPTH
    1 context sentence
    Summary · context
    Teriparatide is a bone anabolic treatment for osteoporosis, modeled in animals by intermittent PTH (iPTH) administration, but the cellular and molecular mechanisms of action of iPTH are largely unknown.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  3. 05AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Mechanism

    In mice, blocking the regulatory T cell increase prevented the improvement in trabecular bone structure induced by intermittent PTH.

    In plain wordsIn mice, blocking the regulatory T cell increase prevented the trabecular bone structure improvement induced by intermittent PTH.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseTreg dependence of trabecular bone structure
    Study

    mousen: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Attesting in vivo relevance, blockade of the Treg increase in mice prevents the increase in bone formation and trabecular bone volume and structure induced by iPTH
    1 context sentence
    Summary · context
    Teriparatide is a bone anabolic treatment for osteoporosis, modeled in animals by intermittent PTH (iPTH) administration, but the cellular and molecular mechanisms of action of iPTH are largely unknown.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.